- RecruitingPHASE3
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
This study looks at new treatments for prostate cancer that has spread. It compares two new approaches with the usual care, hoping to improve how long people live and slow the cancer's spread. It's for men aged 18+.
For: Prostate Cancer MetastaticUnited Kingdom - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
For: Prostatic NeoplasmsUnited States · Austria · Belgium - Active not recruitingPHASE3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard hormone therapy for advanced prostate cancer. It aims to see if the new treatment helps people live longer or keeps their cancer in check for longer, for those who haven't had certain chemotherapy.
For: Prostatic NeoplasmsUnited States · Austria · Belgium